Brazil approves Pfizer's coronavirus vaccine, but has none to use

It is the first coronavirus shot to receive full approval in Brazil, regulator Anvisa said. Vaccines developed by AstraZeneca and China's Sinovac Biotech Ltd, have only been approved for emergency use

Pfizer
The approval is good news for a country whose immunization campaign has been plagued by delays and political squabbling
Reuters
2 min read Last Updated : Feb 23 2021 | 8:42 PM IST
Brazil has fully approved the COVID-19 vaccine developed by Pfizer Inc and BioNTech SE , its health regulator said on Tuesday, though a dispute over a supply deal means it has none to start an immunization program with.
 
It is the first coronavirus shot to receive full approval in Brazil, regulator Anvisa said. Vaccines developed by AstraZeneca and China's Sinovac Biotech Ltd, have only been approved for emergency use.
 
The approval is good news for a country whose immunization campaign has been plagued by delays and political squabbling.
However, it is unclear whether this will pave the way for a supply deal of a highly effective shot that is being rolled out globally.
 
"We hope to be able to move forward in our negotiations with the Brazilian government to support the immunization of the country's population," Pfizer's Brazil boss Marta Diez said in a statement, without giving further details.
 
Brazil's Health Ministry did not respond to a request for comment.
 
President Jair Bolsonaro has criticized the terms of a deal proposed by Pfizer, saying it is overly onerous as it exempts the U.S. firm from potential liability for unforeseen problems.
 
Pfizer has said other countries, including Brazil's neighbors in Latin America, have agreed to those terms.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :BrazilCoronavirus VaccinePfizerAstraZeneca

Next Story